Poster: Applications- Biologicals/vaccines

Artefactual inflation of pharmacokinetic difference between two Granulocyte Colony Stimulating Factor (G-CSF) drug products by non compartmental analysis.

Thursday 16 October, 2025

Objectives: Conventional bioequivalence analysis between Zarzio(r) and Neupogen(r) (two formulations of G-CSF) showed that their Cmax and AUC ratios were…

Read more

Bioequivalence, bootstrapping and case-deletion diagnostics in a biologic: a model-based analysis of the effect of formulation differences in a monoclonal antibody

Thursday 16 October, 2025

Objectives: The primary objective of this work was to ascertain, through an integrated PK/PD model-based approach, whether the pharmacokinetics of…

Read more

Population Pharmacokinetics of AMG 317, a Fully Human Anti-IL-4Rα IgG2 Monoclonal Antibody Evaluated in Healthy and Asthmatic Subjects

Thursday 16 October, 2025

Background: AMG 317 is a fully human IgG2 monoclonal antibody that was tested as a treatment for asthma based on…

Read more

Population Pharmacokinetics of Siplizumab (MEDI-507): Implications for Dosing

Thursday 16 October, 2025

Objectives: Siplizumab (MEDI-507), a humanized IgG1k class monoclonal antibody which targets CD2 expressing T- and NK-cells, is being evaluated in…

Read more

Pharmacokinetics of canakinumab and pharmacodynamics of IL-1β binding in patients with cryopyrin associated periodic fever syndromes

Thursday 16 October, 2025

Objectives: To characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of a fully human anti-IL1β monoclonal antibody (canakinumab, ACZ885) in pediatric…

Read more

Omalizumab (Xolair) may normalise IgE production rate in patients with moderate-to-severe atopic asthma

Thursday 16 October, 2025

Objectives: Long-term anti-IgE therapy may attenuate the excess IgE expression observed in atopic individuals. Methods: We investigated and quantified the…

Read more

On the ability to predict free ligand suppression when free ligand assays are not available or impossible

Thursday 16 October, 2025

Objectives: Monoclonal antibodies are often used to capture soluble target ligands when excess expression causes disease symptoms. Ideally, as in…

Read more

Relationship between omalizumab pharmacokinetics and IgE pharmacodynamics in adult and pediatric patients with moderate to severe persistent allergic (IgE-mediated) asthma

Thursday 16 October, 2025

Objectives: To use a population-based PK-binding model that describes the binding and turnover of omalizumab and IgE to compare the…

Read more

Use of mechanistic models to estimate target antigen load for monoclonal antibodies

Thursday 16 October, 2025

Objectives: Monoclonal antibodies to cell surface targets are characterised by target-mediated non-linear clearance that is saturable at high molar ratios…

Read more

Predicting Free Sclerostin from Free AMG 785 and Total Sclerostin

Thursday 16 October, 2025

Objectives: Therapeutic mAbs often exhibit complex nonlinear pharmacokinetics as a result of the targets’ facilitating their elimination or inactivation. Our…

Read more